Summary & Overview
Reticuloendothelial and Immunity Disorders without CC/MCC: Inpatient Reimbursement Overview
DRG 816 encompasses uncomplicated reticuloendothelial and immunity disorders treated in the inpatient setting and is used to classify cases without Complication or Comorbidity or Major Complication or Comorbidity. Accurate assignment matters for inpatient reimbursement because it influences payment rates under the Medicare inpatient prospective payment methodology and hospital case-mix.
DRG 816 Overview
DRG 816 covers inpatient cases for reticuloendothelial and immunity disorders without Complication or Comorbidity or Major Complication or Comorbidity, including conditions such as uncomplicated immune deficiencies, certain benign hematologic disorders, and related noncomplicated inflammatory processes. It matters for Medicare payment because assignment to this Diagnosis-Related Group typically reflects lower resource use and lower reimbursement relative to cases with complications or comorbidities, impacting hospital revenue and case-mix reporting. Third-party payers and hospitals use this grouping to classify clinical severity and allocate facility payments under the inpatient prospective payment system. Understanding the clinical scope supports accurate coding and claims submission for Medicare beneficiaries.